

References

1. Aarnoudse CA, van den Doel PB, Heemskerk B, Schrier PI (1999) Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1. *Int J Cancer* 82: 442
2. Alves PM, Faure O, Graff-Dubois S, Gross DA, Cornet S, Chouaib S, Miconnet I, Lemonnier FA, Kosmatopoulos K (2003) EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes. *Cancer Res* 63: 8476
3. Andersen MH, Ostergaard Pedersen L, Becker JC, thor Straten P (2000) Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. *Cancer Res* 61: 869-872
4. Andersen MH, Ostergaard Pedersen L, Capeller B, Brocker EB, Becker JC, thor Straten P (2001) Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. *Cancer Res* 61: 5964
5. Anderson BW, Kudelka AP, Honda T, Pollack MS, Gershenson DM, Gillogly MA, Murray JL, Ioannides CG (2000) Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides. *Cancer Immunol Immunother* 49: 459
6. Anichini A, Maccalli C, Mortarini R, Salvi S, Mazzocchi A, Squarcina P, Herlyn M, Parmiani G (1993) Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. *J Exp Med* 177: 989
7. Ashhab Y, Alian A, Polliack A, Panet A, Ben Yehuda D (2001) Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. *FEBS Lett* 495: 56120
8. Ayyoub M, Stevanovic S, Sahin U, Guillaume P, Servis C, Rimoldi D, Valmori D, Romero P, Cerottini JC, Rammensee HG, Pfreundschuh M, Speiser D, Levy F (2002) Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. *J Immunol* 168: 1717

9. Azuma T, Makita M, Ninomiya K, Fujita S, Harada M, Yasukawa M (2002) Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes. *Br J Haematol* 116: 601
10. Azuma K, Shichijo S, Maeda Y, Nakatsura T, Nonaka Y, Fujii T, Koike K, Itoh K (2003) Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B*4601-restricted and tumor cell-reactive CTLs at tumor site. *Cancer Res* 63: 854
11. Bakker AB, Schreurs MW, Tafazzul G, de Boer AJ, Kawakami Y, Adema GJ, Figdor CG (1995) Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line. *Int J Cancer* 62: 97
12. Baurain JF, Colau D, van Baren N, Landry C, Martelange V, Vikkula M, Boon T, Coulie PG (2000) High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene. *J Immunol* 164: 6057
13. Belli F, Testori A, Rivoltini L, Maio M, Andreola G, Sertoli MR, Gallino G, Piris A, Cattelan A, Lazzari I, Carrabba M, Scita G, Santantonio C, Pilla L, Tragni G, Lombardo C, Arienti F, Marchiano A, Queirolo P, Bertolini F, Cova A, Lamaj E, Ascani L, Camerini R, Corsi M, Cascinelli N, Lewis JJ, Srivastava P, Parmiani G (2002) Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. *J Clin Oncol* 20: 4169
14. Benlalam H, Linard B, Guilloux Y, Moreau-Aubry A, Derre L, Diez E, Dreno B, Jotereau F, Labarriere N (2003) Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes. *J Immunol* 171: 6283
15. Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A, Scheinberg DA (1996) Specific human cellular immunity to bcr-abl oncogene-derived peptides. *Blood* 87: 3587
16. Boel P, Wildmann C, Sensi ML, Basseur R, Renauld JC, Coulie P, Boon T, van der Bruggen P (1995) BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. *Immunity* 2: 167

17. Bohm CM, Hanski ML, Stefanovic S, Rammensee HG, Stein H, Taylor-Papadimitriou J, Riecken EO, Hanski C (1998) Identification of HLA-A2-restricted epitopes of the tumor-associated antigen MUC2 recognized by human cytotoxic T cells. *Int J Cancer* 75: 688
18. Boon T, van der Bruggen P (1996) Human tumor antigens recognized by T lymphocytes. *J Exp Med* 183: 725
19. Brandle D, Brasseur F, Weynants P, Boon T, Van den Eynde B (1996) A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. *J Exp Med* 183: 2501
20. Brichard VG, Herman J, Van Pel A, Wildmann C, Gaugler B, Wolfel T, Boon T, Lethé B (1996) A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. *Eur J Immunol* 26: 224
21. Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L, Brugger W (1999) Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. *Blood* 93: 4309
22. Butterfield LH, Koh A, Meng W, Vollmer CM, Ribas A, Dissette V, Lee E, Glaspy JA, McBride WH, Economou JS (1999) Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. *Cancer Res* 59: 3134
23. Buzyn A, Ostankovitch M, Zerbib A, Kemula M, Connan F, Varet B, Guillet JG, Choppin J (1997) Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes. *Eur J Immunol* 27: 2066
24. Campi G, Crosti M, Consogno G, Facchinetti V, Conti-Fine BM, Longhi R, Casorati G, Dellabona P, Protti MP (2003) CD4(+) T cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope. *Cancer Res* 63: 8481
25. Casati C, Dalerba P, Rivoltini L, Gallino G, Deho P, Rini F, Belli F, Mezzanzanica D, Costa A, Andreola S, Leo E, Parmiani G, Castelli C (2003) The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. *Cancer Res* 63: 4507
26. Castelli C, Storkus WJ, Maeurer MJ, Martin DM, Huang EC, Pramanik BN, Nagabhushan TL, Parmiani G, Lotze MT (1995) Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. *J Exp Med* 181: 363

27. Castelli C, Tarsini P, Mazzocchi A, Rini F, Rivoltini L, Ravagnani F, Gallino F, Belli F, Parmiani G (1999) Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens. *J Immunol* 162: 1739
28. Chaux P, Luiten R, Demotte N, Vantomme V, Stroobant V, Traversari C, Russo V, Schultz E, Cornelis GR, Boon T, van der Bruggen P (1999) Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. *J Immunol* 163: 2928
29. Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, Eggermont AM, Boon T, van der Bruggen P (1999) Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. *J Exp Med* 189: 767
30. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. *Proc Natl Acad Sci USA* 94: 1914
31. Chiari R, Foury F, De Plaen E, Baurain JF, Thonnard J, Coulie PG (1999) Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene. *Cancer Res* 59: 5785
32. Chiari R, Hames G, Stroobant V, Texier C, Maillere B, Boon T, Coulie PG (2000) Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules. *Cancer Res* 60: 4855
33. Consogno G, Manici S, Facchinetti V, Bachi A, Hammer J, Conti-Fine BM, Rugarli C, Traversari C, Protti MP (2003) Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3. *Blood* 101: 1038
34. Corman JM, Sercarz EE, Nanda NK (1998) Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells. *Clin Exp Immunol* 114: 166
35. Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY (1997) In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. *J Natl Cancer Inst* 89: 293

36. Coulie PG, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C, Mattei S, De Plaen E, Lurquin C, Szikora JP, Renauld JC, Boon T (1994) A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. *J Exp Med* 180: 35
37. Coulie PG, Lehmann F, Lethe B, Herman J, Lurquin C, Andrawiss M, Boon T (1995) A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. *Proc Natl Acad Sci USA* 92: 7976
38. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL Jr (1994) Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. *Science* 264: 716
39. Dabovic B, Zanaria E, Bardoni B, Lisa A, Bordignon C, Russo V, Matessi C, Traversari C, Camerino G (1995) A family of rapidly evolving genes from the sex reversal critical region in Xp21. *Mamm Genome* 6: 571
40. De Backer O, Arden KC, Boretti M, Vantomme V, De Smet C, Czekay S, Viars CS, De Plaen E, Brasseur F, Chomez P, Van den Eynde B, Boon T, van der Bruggen P (1999) Characterization of the GAGE genes that are expressed in various human cancers and in normal testis. *Cancer Res* 59: 3157
41. De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De Smet C, Brasseur F, van der Bruggen P, Lethe B, Lurquin C, Brasseur R, Chomez P, De Backer O, Cavenee W, Boon T (1994) Structure, chromosomal localization, and expression of 12 genes of the MAGE family. *Immunogenetics* 40: 360
42. De Smet C, Lurquin C, van der Bruggen P, De Plaen E, Brasseur F, Boon T (1994) Sequence and expression pattern of the human MAGE2 gene. *Immunogenetics* 39: 121
43. De Smet C, Lurquin C, Lethe B, Martelange V, Boon T (1999) DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. *Mol Cell Biol* 19: 7327
44. Dermime S, Bertazzoli C, Marchesi E, Ravagnani F, Blaser K, Corneo GM, Pogliani E, Parmiani G, Gambacorti-Passerini C (1996) Lack of T-cell-mediated recognition of the fusion region of the pml/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia patients. *Clin Cancer Res* 2: 593

45. Domenech N, Henderson RA, Finn OJ (1995) Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. *J Immunol* 155: 4766
46. Dreier R, Schmid KW, Gerke V, Riehm K (1998) Differential expression of annexins I, II and IV in human tissues: an immunohistochemical study. *Histochem Cell Biol* 110: 137
47. Dudley ME, Roopenian DC (1996) Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens. *J Exp Med* 184: 441
48. Duffour MT, Chauv P, Lurquin C, Cornelis G, Boon T, van der Bruggen P (1999) A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes. *Eur J Immunol* 29: 3329
49. Echchakir H, Mami-Chouaib F, Vergnon I, Baurain JF, Karanikas V, Chouaib S, Coulie PG (2001) A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. *Cancer Res* 61: 4078
50. Fisk B, Blevins TL, Wharton JT, Ioannides CG (1995) Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. *J Exp Med* 181: 2109
51. Fleischhauer K, Fruci D, Van Endert P, Herman J, Tanzarella S, Wallny HJ, Coulie P, Bordignon C, Traversari C (1996) Characterization of antigenic peptides presented by HLA-B44 molecules on tumor cells expressing the gene MAGE-3. *Int J Cancer* 68: 622
52. Fleischhauer K, Gattinoni L, Dalerba P, Lauvau G, Zanaria E, Dabovic B, van Endert PM, Bordignon C, Traversari C (1998) The DAM gene family encodes a new group of tumor-specific antigens recognized by human leukocyte antigen A2-restricted cytotoxic T lymphocytes. *Cancer Res* 58: 2969
53. Fujie T, Tahara K, Tanaka F, Mori M, Takesako K, Akiyoshi T (1999) A MAGE-1-encoded HLA-A24-binding synthetic peptide induces specific anti-tumor cytotoxic T lymphocytes. *Int J Cancer* 80: 169
54. Gambacorti-Passerini C, Grignani F, Arienti F, Pandolfi PP, Pelicci PG, Parmiani G (1993) Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells. *Blood* 81: 1369

55. Gaudin C, Kremer F, Angevin E, Scott V, Triebel F (1999) A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma. *J Immunol* 162: 1730
56. Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethe B, Brasseur F, Boon T (1994) Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. *J Exp Med* 179: 921
57. Gaugler B, Brouwenstijn N, Vantomme V, Szikora JP, Van der Spek CW, Patard JJ, Boon T, Schrier P, Van den Eynde BJ (1996) A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. *Immunogenetics* 44: 323
58. Gazzaniga P, Gradilone A, Giuliani L, Gandini O, Silvestri I, Nofroni I, Saccani G, Frati L, Agliano AM (2003) Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. *Ann Oncol* 14: 85
59. Gjertsen MK, Bjorheim J, Saeterdal I, Myklebust J, Gaudernack G (1997) Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. *Int J Cancer* 72: 784
60. Gomi S, Nakao M, Niiya F, Imamura Y, Kawano K, Nishizaka S, Hayashi A, Sobao Y, Oizumi K, Itoh K (1999) A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs. *J Immunol* 163: 4994
61. Greco G, Fruci D, Accapezzato D, Barnaba V, Nisini R, Alimena G, Montefusco E, Vigneti E, Butler R, Tanigaki N, Tosi R (1996) Two bcr-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. *Leukemia* 10: 693
62. Gueguen M, Patard JJ, Gaugler B, Brasseur F, Renauld JC, Van Cangh PJ, Boon T, Van den Eynde BJ (1998) An antigen recognized by autologous CTLs on a human bladder carcinoma. *J Immunol* 160: 6188
63. Guilloux Y, Lucas S, Brichard VG, Van Pel A, Viret C, De Plaen E, Brasseur F, Lethe B, Jotereau F, Boon T (1996) A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyl-transferase V gene. *J Exp Med* 183: 1173

64. Gure AO, Stockert E, Arden KC, Boyer AD, Viars CS, Scanlan MJ, Old LJ, Chen YT (2000) CT10: a new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational-difference analysis. *Int J Cancer* 85: 726
65. Hanada K, Yewdell JW, Yang JC (2004) Immune recognition of a human renal cancer antigen through post-translational protein splicing. *Nature* 427: 252
66. Harada M, Li YF, El-Gamil M, Ohnmacht GA, Rosenberg SA, Robbins PF (2001) Melanoma-reactive CD8+ T cells recognize a novel tumor antigen expressed in a wide variety of tumor types. *J Immunother* 24: 323
67. Heidecker L, Brasseur F, Probst-Kepper M, Gueguen M, Boon T, Van den Eynde BJ (2000) Cytolytic T lymphocytes raised against a human bladder carcinoma recognize an antigen encoded by gene MAGE-A12. *J Immunol* 164: 6041
68. Herman J, van der Bruggen P, Luescher IF, Mandruzzato S, Romero P, Thonnard J, Fleischhauer K, Boon T, Coulie PG (1996) A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. *Immunogenetics* 43: 377
69. Hiltbold EM, Ciborowski P, Finn OJ (1998) Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells. *Cancer Res* 58: 5066
70. Hirohashi Y, Torigoe T, Maeda A, Nabeta Y, Kamiguchi K, Sato T, Yoda J, Ikeda H, Hirata K, Yamanaka N, Sato N (2002) An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. *Clin Cancer Res* 8: 1731
71. Hogan KT, Eisinger DP, Cupp SB 3rd, Lekstrom KJ, Deacon DD, Shabanowitz J, Hunt DF, Engelhard VH, Slingluff CL Jr, Ross MM (1998) The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene. *Cancer Res* 58: 5144
72. Horiguchi Y, Nukaya I, Okazawa K, Kawashima I, Fikes J, Sette A, Tachibana M, Takesako K, Murai M (2002) Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes. *Clin Cancer Res* 8: 3885

73. Huang LQ, Brasseur F, Serrano A, De Plaen E, van der Bruggen P, Boon T, Van Pel A (1999) Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma. *J Immunol* 162: 6849
74. Ikeda H, Lethé B, Lehmann F, van Baren N, Baurain JF, de Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. *Immunity* 6: 199
75. Ishikawa T, Kashiwagi H, Iwakami Y, Hirai M, Kawamura T, Aiyoshi Y, Yashiro T, Ami Y, Uchida K, Miwa M (1998) Expression of alpha-fetoprotein and prostate-specific antigen genes in several tissues and detection of mRNAs in normal circulating blood by reverse transcriptase-polymerase chain reaction. *Jpn J Clin Oncol* 28: 723
76. Ito M, Shichijo S, Miyagi Y, Kobayashi T, Tsuda N, Yamada A, Saito N, Itoh K (2000) Identification of SART3-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with different HLA-A2 subtypes. *Int J Cancer* 88: 633
77. Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A (1998) Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. *J Exp Med* 187: 265
78. Jager E, Jager D, Karbach J, Chen YT, Ritter G, Nagata Y, Gnjjatic S, Stockert E, Arand M, Old LJ, Knuth A (2000) Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. *J Exp Med* 191: 625
79. Jaramillo A, Majumder K, Manna PP, Fleming TP, Doherty G, Dipersio JF, Mohanakumar T (2002) Identification of HLA-A3-restricted CD8+ T cell epitopes derived from mammapoglobin-A, a tumor-associated antigen of human breast cancer. *Int J Cancer* 102: 499
80. Jassim A, Ollier W, Payne A, Biro A, Oliver RT, Festenstein H (1989) Analysis of HLA antigens on germ cells in human semen. *Eur J Immunol* 19: 1215

81. Kang X, Kawakami Y, el-Gamil M, Wang R, Sakaguchi K, Yannelli JR, Appella E, Rosenberg SA, Robbins PF (1995) Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. *J Immunol* 155: 1343
82. Karanikas V, Colau D, Baurain JF, Chiari R, Thonnard J, Gutierrez-Roelens I, Goffinet C, Van Schaftingen EV, Weynants P, Boon T, Coulie PG (2001) High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. *Cancer Res* 61: 3718
83. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA (1994) Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. *Proc Natl Acad Sci USA* 91: 3515
84. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA (1994) Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. *Proc Natl Acad Sci USA* 91: 6458
85. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA (1994) Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. *J Exp Med* 180: 347
86. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA (1995) Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. *J Immunol* 154: 3961
87. Kawakami Y, Rosenberg SA (1997) Human tumor antigens recognized by T-cells. *Immunol Res* 16: 313
88. Kawakami Y, Robbins PF, Wang X, Tupesis JP, Parkhurst MR, Kang X, Sakaguchi K, Appella E, Rosenberg SA (1998) Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. *J Immunol* 161: 6985

89. Kawakami Y, Wang X, Shofuda T, Sumimoto H, Tupesis J, Fitzgerald E, Rosenberg S (2001) Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes. *J Immunol* 166: 2871
90. Kawano K, Gomi S, Tanaka K, Tsuda N, Kamura T, Itoh K, Yamada A (2000) Identification of a new endoplasmic reticulum-resident protein recognized by HLA-A24-restricted tumor-infiltrating lymphocytes of lung cancer. *Cancer Res* 60: 3550
91. Kawashima I, Tsai V, Southwood S, Takesako K, Celis E, Sette A (1998) Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells. *Int J Cancer* 78: 518
92. Kawashima I, Tsai V, Southwood S, Takesako K, Sette A, Celis E (1999) Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. *Cancer Res* 59: 431
93. Kessler JH, Beekman NJ, Bres-Vloemans SA, Verdijk P, van Veelen PA, Kloosterman-Joosten AM, Vissers DC, ten Bosch GJ, Kester MG, Sijts A, Wouter Drijfhout J, Ossendorp F, Offringa R, Melief CJ (2001) Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. *J Exp Med* 193: 73
94. Khong HT, Rosenberg SA (2002) Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy. *J Immunol* 168: 951
95. Khong HT, Rosenberg SA (2002) The Waardenburg syndrome type 4 gene, SOX10, is a novel tumor-associated antigen identified in a patient with a dramatic response to immunotherapy. *Cancer Res* 62: 3020
96. Kierstead LS, Ranieri E, Olson W, Brusic V, Sidney J, Sette A, Kasamon YL, Slingluff CL Jr, Kirkwood JM, Storkus WJ (2001) gp100/pm17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells. *Br J Cancer* 85: 1738

97. Kikuchi M, Nakao M, Inoue Y, Matsunaga K, Shichijo S, Yamana H, Itoh K (1999) Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes. *Int J Cancer* 81: 459
98. Kikumoto Y, Oka T, Cao JN, Sze L, Irie RF (1995) Peptides with carboxyl-terminal sequence of alanine-proline: detection by a human monoclonal antibody. *Hybridoma* 14: 45
99. Kittlesen DJ, Thompson LW, Gulden PH, Skipper JC, Colella TA, Shabanowitz J, Hunt DF, Engelhard VH, Slingluff CL Jr, Shabanowitz JA (1998) Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development. *J Immunol* 160: 2099
100. Knights AJ, Zaniou A, Rees RC, Pawelec G, Muller L (2002) Prediction of an HLA-DR-binding peptide derived from Wilms' tumour 1 protein and demonstration of in vitro immunogenicity of WT1(124-138)-pulsed dendritic cells generated according to an optimised protocol. *Cancer Immunol Immunother* 51: 271
101. Kobayashi H, Kokubo T, Sato K, Kimura S, Asano K, Takahashi H, Iizuka H, Miyokawa N, Katagiri M (1998) CD4+ T cells from peripheral blood of a melanoma patient recognize peptides derived from nonmutated tyrosinase. *Cancer Res* 58: 296
102. Kobayashi H, Kokubo T, Takahashi M, Sato K, Miyokawa N, Kimura S, Kinouchi R, Katagiri M (1998) Tyrosinase epitope recognized by an HLA-DR-restricted T-cell line from a Vogt-Koyanagi-Harada disease patient. *Immunogenetics* 47: 398
103. Kobayashi H, Omiya R, Ruiz M, Huarte E, Sarobe P, Lasarte JJ, Herraiz M, Sangro B, Prieto J, Borrás-Cuesta F, Celis E (2002) Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. *Clin Cancer Res* 8: 3219
104. Kono K, Rongcun Y, Charo J, Ichihara F, Celis E, Sette A, Appella E, Sekikawa T, Matsumoto Y, Kiessling R (1998) Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. *Int J Cancer* 78: 202
105. Konopitzky R, König U, Meyer RG, Sommergruber W, Wolfel T, Schweighoffer T (2002) Identification of HLA-A*0201-restricted T cell epitopes derived from the novel overexpressed tumor antigen calcium-activated chloride channel 2. *J Immunol* 169: 540

106. Lapointe R, Royal RE, Reeves ME, Altomare I, Robbins PF, Hwu P (2001) Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100. *J Immunol* 167: 4758
107. Lethe B, Lucas S, Michaux L, De Smet C, Godelaine D, Serrano A, De Plaen E, Boon T (1998) LAGE-1, a new gene with tumor specificity. *Int J Cancer* 76: 903
108. Li K, Adibzadeh M, Halder T, Kalbacher H, Heinzl S, Muller C, Zeuthen J, Pawelec G (1998) Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells. *Cancer Immunol Immunother* 47: 32
109. Linard B, Bezieau S, Benlalam H, Labarriere N, Guilloux Y, Diez E, Jotereau F (2002) A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion. *J Immunol* 168: 4802
110. Linnebacher M, Gebert J, Rudy W, Woerner S, Yuan YP, Bork P, von Knebel Doeberitz M (2001) Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. *Int J Cancer* 93: 6
111. Liu G, Khong HT, Wheeler CJ, Yu JS, Black KL, Ying H (2003) Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma. *J Immunother* 26: 301
112. Lucas S, Brasseur F, Boon T (1999) A new MAGE gene with ubiquitous expression does not code for known MAGE antigens recognized by T cells. *Cancer Res* 59: 4100
113. Lucas S, De Plaen E, Boon T (2000) MAGE-B5, MAGE-B6, MAGE-C2, and MAGE-C3: four new members of the MAGE family with tumor-specific expression. *Int J Cancer* 87: 55
114. Lupetti R, Pisarra P, Verrecchia A, Farina C, Nicolini G, Anichini A, Bordignon C, Sensi M, Parmiani G, Traversari C (1998) Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage. *J Exp Med* 188: 1005
115. Lurquin C, De Smet C, Brasseur F, Muscatelli F, Martelange V, De Plaen E, Brasseur R, Monaco AP, Boon T (1997) Two members of the human MAGEB gene family located in Xp21.3 are expressed in tumors of various histological origins. *Genomics* 46: 397

116. Mandruzzato S, Brasseur F, Andry G, Boon T, van der Bruggen P (1997) A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. *J Exp Med* 186: 785
117. Manici S, Sturniolo T, Imro MA, Hammer J, Sinigaglia F, Noppen C, Spagnoli G, Mazzi B, Bellone M, Dellabona P, Protti MP (1999) Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. *J Exp Med* 189: 871
118. Martelange V, De Smet C, De Plaen E, Lurquin C, Boon T (2000) Identification on a human sarcoma of two new genes with tumor-specific expression. *Cancer Res* 60: 3848
119. Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M (2000) Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. *Proc Natl Acad Sci USA* 97: 4796
120. Moreau-Aubry A, Le Guiner S, Labarriere N, Gesnel MC, Jotereau F, Breathnach R (2000) A processed pseudogene codes for a new antigen recognized by a CD8(+) T cell clone on melanoma. *J Exp Med* 191: 1617
121. Morel S, Levy F, Bulet-Schiltz O, Brasseur F, Probst-Kepper M, Peitrequin AL, Monsarrat B, Van Velthoven R, Cerottini JC, Boon T, Gairin JE, Van den Eynde BJ (2000) Processing of some antigens by the standard proteasome but not by the immuno-proteasome results in poor presentation by dendritic cells. *Immunity* 12: 107
122. Morioka N, Kikumoto Y, Hoon DS, Morton DL, Irie RF (1995) Cytotoxic T cell recognition of a human melanoma derived peptide with a carboxyl-terminal alanine-proline sequence. *Mol Immunol* 32: 573
123. Nagorsen D, Keilholz U, Rivoltini L, Schmittel A, Letsch A, Asemissen AM, Berger G, Buhr HJ, Thiel E, Scheibenbogen C (2000) Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. *Cancer Res* 60: 4850
124. Nakao M, Shichijo S, Imaizumi T, Inoue Y, Matsunaga K, Yamada A, Kikuchi M, Tsuda N, Ohta K, Takamori S, Yamana H, Fujita H, Itoh K (2000) Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL. *J Immunol* 164: 2565

125. Noppen C, Levy F, Burri L, Zajac P, Remmel E, Schaefer C, Luscher U, Heberer M, Spagnoli GC (2000) Naturally processed and concealed HLA-A2.1-restricted epitopes from tumor-associated antigen tyrosinase-related protein-2. *Int J Cancer* 87: 241
126. Norbury LC, Clark RE, Christmas SE (2000) b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia. *Br J Haematol* 109: 616
127. Novellino L, Renkvist N, Rini F, Mazzocchi A, Rivoltini L, Greco A, Deho P, Squarcina P, Robbins PF, Parmiani G, Castelli C (2003) Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen. *J Immunol* 170: 6363
128. Ohkouchi S, Kawamoto N, Koga M, Sakanashi F, Shichijo S, Saijo Y, Nukiwa T, Itoh K, Yamada A (2003) Identification of a CTL-directed epitope encoded by an intron of the putative tumor suppressor gene Testin of the common fragile site 7G region: a peptide vaccine candidate for HLA-B52+ and HLA-62+ cancer patients. *Eur J Immunol* 33: 2964
129. Ohminami H, Yasukawa M, Kaneko S, Yakushijin Y, Abe Y, Kasahara Y, Ishida Y, Fujita S (1999) Fas-independent and nonapoptotic cytotoxicity mediated by a human CD4(+) T-cell clone directed against an acute myelogenous leukemia-associated DEK-CAN fusion peptide. *Blood* 93: 925
130. Ohminami H, Yasukawa M, Fujita S (2000) HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. *Blood* 95: 286
131. Oiso M, Eura M, Katsura F, Takiguchi M, Sobao Y, Masuyama K, Nakashima M, Itoh K, Ishikawa T (1999) A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes. *Int J Cancer* 81: 387
132. Oka Y, Elisseeva OA, Tsuboi A, Ogawa H, Tamaki H, Li H, Oji Y, Kim EH, Soma T, Asada M, Ueda K, Maruya E, Saji H, Kishimoto T, Udaka K, Sugiyama H (2000) Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. *Immunogenetics* 51: 99
133. Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H (2002) Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. *Clin Cancer Res* 8: 2851

134. Okugawa T, Ikuta Y, Takahashi Y, Obata H, Tanida K, Watanabe M, Imai S, Furugen R, Nagata Y, Toyoda N, Shiku H (2000) A novel human HER2-derived peptide homologous to the mouse K(d)-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals. *Eur J Immunol* 30: 3338
135. Old LJ (2001) Cancer/testis (CT) antigens - a new link between gametogenesis and cancer. *Cancer Immunity* 1: 1
136. Panelli MC, Bettinotti MP, Lally K, Ohnmacht GA, Li Y, Robbins P, Riker A, Rosenberg SA, Marincola FM (2000) A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12. *J Immunol* 164: 4382
137. Parkhurst MR, Fitzgerald EB, Southwood S, Sette A, Rosenberg SA, Kawakami Y (1998) Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). *Cancer Res* 58: 4895
138. Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoltini L, Marincola FM, Anichini A (2002) Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? *J Natl Cancer Inst* 94: 805
139. Passoni L, Scardino A, Bertazzoli C, Gallo B, Coluccia AM, Lemonnier FA, Kosmatopoulos K, Gambacorti-Passerini C (2002) ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes. *Blood* 99: 2100
140. Pawelec G, Max H, Halder T, Bruserud O, Merl A, da Silva P, Kalbacher H (1996) BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. *Blood* 88: 2118
141. Peiper M, Goedegebuure PS, Linehan DC, Ganguly E, Douville CC, Eberlein TJ (1997) The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes. *Eur J Immunol* 27: 1115
142. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ (1995) Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. *Proc Natl Acad Sci USA* 92: 432

143. Pieper R, Christian RE, Gonzales MI, Nishimura MI, Gupta G, Settlege RE, Shabanowitz J, Rosenberg SA, Hunt DF, Topalian SL (1999) Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells. *J Exp Med* 189: 757
144. Pisarra P, Lupetti R, Palumbo A, Napolitano A, Prota G, Parmiani G, Anichini A, Sensi M (2000) Human melanocytes and melanomas express novel mRNA isoforms of the tyrosinase-related protein-2/DOPAchrome tautomerase gene: molecular and functional characterization. *J Invest Dermatol* 115: 48
145. Probst-Kepper M, Stroobant V, Kridel R, Gaugler B, Landry C, Brasseur F, Cosyns JP, Weynand B, Boon T, Van Den Eynde BJ (2001) An alternative open reading frame of the human macrophage colony-stimulating factor gene is independently translated and codes for an antigenic peptide of 14 amino acids recognized by tumor-infiltrating CD8 T lymphocytes. *J Exp Med* 193: 1189
146. Ripberger E, Linnebacher M, Schwitalle Y, Gebert J, von Knebel Doeberitz M (2003) Identification of an HLA-A0201-restricted CTL epitope generated by a tumor-specific frameshift mutation in a coding microsatellite of the OGT gene. *J Clin Immunol* 23: 415
147. Robbins PF, el-Gamil M, Li YF, Topalian SL, Rivoltini L, Sakaguchi K, Appella E, Kawakami Y, Rosenberg SA (1995) Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. *J Immunol* 154: 5944
148. Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, Appella E, Rosenberg SA (1996) A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. *J Exp Med* 183: 1185
149. Robbins PF, El-Gamil M, Li YF, Fitzgerald EB, Kawakami Y, Rosenberg SA (1997) The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. *J Immunol* 159: 303
150. Robbins P (2002) Immune recognition of cancer - Tumor antigens. In: Parmiani G & Lotze MT (eds) *Tumor immunology: molecularly defined antigens and clinical applications*. Harwood Acad Publ, London, p 11
151. Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Maes H, Kono K, Hising C, Petersson M, Larsson O, Lan L, Appella E, Sette A, Celis E, Kiessling R (1999) Identification of

- new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. *J Immunol* 163: 1037
152. Ronsin C, Chung-Scott V, Poullion I, Aknouche N, Gaudin C, Triebel F (1999) A non-AUG-defined alternative open reading frame of the intestinal carboxyl esterase mRNA generates an epitope recognized by renal cell carcinoma-reactive tumor-infiltrating lymphocytes in situ. *J Immunol* 163: 483
153. Rosenberg SA, Tong-On P, Li Y, Riley JP, El-Gamil M, Parkhurst MR, Robbins PF (2002) Identification of BING-4 cancer antigen translated from an alternative open reading frame of a gene in the extended MHC class II region using lymphocytes from a patient with a durable complete regression following immunotherapy. *J Immunol* 168: 2402
154. Russo V, Tanzarella S, Dalerba P, Rigatti D, Rovere P, Villa A, Bordignon C, Traversari C (2000) Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. *Proc Natl Acad Sci USA* 97: 2185
155. Saeterdal I, Bjorheim J, Lislerud K, Gjertsen MK, Bukholm IK, Olsen OC, Nesland JM, Eriksen JA, Moller M, Lindblom A, Gaudernack G (2001) Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. *Proc Natl Acad Sci USA* 98: 13255
156. Salazar-Onfray F, Nakazawa T, Chhajlani V, Petersson M, Karre K, Masucci G, Celis E, Sette A, Southwood S, Appella E, Kiessling R (1997) Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells. *Cancer Res* 57: 4348
157. Scanlan MJ, Altorki NK, Gure AO, Williamson B, Jungbluth A, Chen YT, Old LJ (2000) Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. *Cancer Lett* 150: 155
158. Schmidt SM, Schag K, Muller MR, Weck MM, Appel S, Kanz L, Grunebach F, Brossart P (2003) Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. *Blood* 102: 571
159. Schmidt SM, Schag K, Muller MR, Weinschenk T, Appel S, Schoor O, Weck MM, Grunebach F, Kanz L, Stevanovic S, Rammensee HG, Brossart P (2004) Induction of adipophilin-specific

- cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis. *Cancer Res* 64: 1164
160. Schmitz M, Diestelkoetter P, Weigle B, Schmachtenberg F, Stevanovic S, Ockert D, Rammensee HG, Rieber EP (2000) Generation of survivin-specific CD8⁺ T effector cells by dendritic cells pulsed with protein or selected peptides. *Cancer Res* 60: 4845
161. Schmollinger JC, Vonderheide RH, Hoar KM, Maecker B, Schultze JL, Hodi FS, Soiffer RJ, Jung K, Kuroda MJ, Letvin NL, Greenfield EA, Mihm M, Kutok JL, Dranoff G (2003) Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. *Proc Natl Acad Sci USA* 100: 3398
162. Schneider J, Brichard V, Boon T, Meyer zum Buschenfelde KH, Wolfel T (1998) Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1. *Int J Cancer* 75: 451
163. Sensi M, Pellegatta S, Vegetti C, Nicolini G, Parmiani G, Anichini A (2002) Identification of a novel gp100/pMel17 peptide presented by HLA-A*6801 and recognized on human melanoma by cytolytic T cell clones. *Tissue Antigens* 59: 273
164. Shichijo S, Nakao M, Imai Y, Takasu H, Kawamoto M, Niiya F, Yang D, Toh Y, Yamana H, Itoh K (1998) A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. *J Exp Med* 187: 277
165. Skipper JC, Kittlesen DJ, Hendrickson RC, Deacon DD, Harthun NL, Wagner SN, Hunt DF, Engelhard VH, Slingluff CL Jr (1996) Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100. *J Immunol* 157: 5027
166. Slager EH, Borghi M, van der Minne CE, Aarnoudse CA, Havenga MJ, Schrier PI, Osanto S, Griffioen M (2003) CD4⁺ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame. *J Immunol* 170: 1490
167. Suzuki K, Sahara H, Okada Y, Yasoshima T, Hirohashi Y, Nabeta Y, Hirai I, Torigoe T, Takahashi S, Matsuura A, Takahashi N, Sasaki A, Suzuki M, Hamuro J, Ikeda H, Wada Y, Hirata K, Kikuchi K, Sato N (1999) Identification of natural antigenic peptides of a human gastric signet ring cell carcinoma recognized by HLA-A31-restricted cytotoxic T lymphocytes. *J Immunol* 163: 2783

168. Tahara K, Takesako K, Sette A, Celis E, Kitano S, Akiyoshi T (1999) Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes. *Clin Cancer Res* 5: 2236
169. Tanaka F, Fujie T, Tahara K, Mori M, Takesako K, Sette A, Celis E, Akiyoshi T (1997) Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24. *Cancer Res* 57: 4465
170. Tanaka Y, Takahashi T, Nieda M, Masuda S, Kashiwase K, Ogawa S, Chiba S, Juji T, Hirai H (2000) Generation of HLA-DRB1*1501-restricted p190 minor bcr-abl (e1a2)-specific CD4+ T lymphocytes. *Br J Haematol* 109: 435
171. Tanzarella S, Russo V, Lionello I, Dalerba P, Rigatti D, Bordignon C, Traversari C (1999) Identification of a promiscuous T-cell epitope encoded by multiple members of the MAGE family. *Cancer Res* 59: 2668
172. Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH, Bukowski RM, Brusic V, Sidney J, Sette A, Logan TF, Kasamon YL, Slingluff CL Jr, Kirkwood JM, Storkus WJ (2003) MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. *Clin Cancer Res* 9: 947
173. ten Bosch GJ, Toornvliet AC, Friede T, Melief CJ, Leeksa OC (1995) Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells. *Leukemia* 9: 1344
174. ten Bosch GJ, Joosten AM, Kessler JH, Melief CJ, Leeksa OC (1996) Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. *Blood* 88: 3522
175. ten Bosch GJ, Kessler JH, Joosten AM, Bres-Vloemans AA, Geluk A, Godthelp BC, van Bergen J, Melief CJ, Leeksa OC (1999) A BCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Ii(b2a2) construct. *Blood* 94: 1038
176. Topalian SL, Rivoltini L, Mancini M, Markus NR, Robbins PF, Kawakami Y, Rosenberg SA (1994) Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. *Proc Natl Acad Sci USA* 91: 9461

177. Topalian SL, Gonzales MI, Parkhurst M, Li YF, Southwood S, Sette A, Rosenberg SA, Robbins PF (1996) Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. *J Exp Med* 183: 1965
178. Topalian SL, Gonzales MI, Ward Y, Wang X, Wang RF (2002) Revelation of a cryptic major histocompatibility complex class II-restricted tumor epitope in a novel RNA-processing enzyme. *Cancer Res* 62: 5505
179. Touloukian CE, Leitner WW, Robbins PF, Rosenberg SA, Restifo NP (2001) Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor-associated antigen. *Cancer Res* 61: 8100
180. Touloukian CE, Leitner WW, Schnur RE, Robbins PF, Li Y, Southwood S, Sette A, Rosenberg SA, Restifo NP (2003) Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1. *J Immunol* 170: 1579
181. Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T (1992) A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. *J Exp Med* 176: 1453
182. Tsai V, Southwood S, Sidney J, Sakaguchi K, Kawakami Y, Appella E, Sette A, Celis E (1997) Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. *J Immunol* 158: 1796
183. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J (1995) Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. *J Natl Cancer Inst* 87: 982
184. Umamo Y, Tsunoda T, Tanaka H, Matsuda K, Yamaue H, Tanimura H (2001) Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53. *Br J Cancer* 84: 1052
185. van Baren N, Chambost H, Ferrant A, Michaux L, Ikeda H, Millard I, Olive D, Boon T, Coulie PG (1998) PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. *Br J Haematol* 102: 1376

186. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T (1995) A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. *J Exp Med* 182: 689
187. Van den Eynde BJ, Gaugler B, Probst-Kepper M, Michaux L, Devuyst O, Lorge F, Weynants P, Boon T (1999) A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription. *J Exp Med* 190: 1793
188. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. *Science* 254: 1643
189. van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boel P, De Smet C, Traversari C, Townsend A, Boon T (1994) A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. *Eur J Immunol* 24: 3038
190. van der Bruggen P, Szikora JP, Boel P, Wildmann C, Somville M, Sensi M, Boon T (1994) Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601. *Eur J Immunol* 24: 2134
191. van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, Van Den Eynde BJ, Brasseur F, Boon T (2002) Tumor-specific shared antigenic peptides recognized by human T cells. *Immunol Rev* 188: 51
192. Vigneron N, Ooms A, Morel S, Degiovanni G, Van Den Eynde BJ (2002) Identification of a new peptide recognized by autologous cytolytic T lymphocytes on a human melanoma. *Cancer Immunol* 2: 9
193. Visseren MJ, van der Burg SH, van der Voort EI, Brandt RM, Schrier PI, van der Bruggen P, Boon T, Melief CJ, Kast WM (1997) Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product. *Int J Cancer* 73: 125
194. Vissers JL, De Vries IJ, Schreurs MW, Engelen LP, Oosterwijk E, Figdor CG, Adema GJ (1999) The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. *Cancer Res* 59: 5554

195. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM (1999) The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. *Immunity* 10: 673
196. Vonderheide RH, Anderson KS, Hahn WC, Butler MO, Schultze JL, Nadler LM (2001) Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. *Clin Cancer Res* 7: 3343
197. Vucic D, Stennicke HR, Pisabarro MT, Salvesen GS, Dixit VM (2000) ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. *Curr Biol* 10: 1359
198. Wagner WM, Ouyang Q, Pawelec G (2003) The abl/bcr gene product as a novel leukemia-specific antigen: peptides spanning the fusion region of abl/bcr can be recognized by both CD4+ and CD8+ T lymphocytes. *Cancer Immunol Immunother* 52: 89
199. Wang HY, Zhou J, Zhu K, Riker AI, Marincola FM, Wang RF (2002) Identification of a mutated fibronectin as a tumor antigen recognized by CD4+ T cells: its role in extracellular matrix formation and tumor metastasis. *J Exp Med* 195: 1397
200. Wang HY, Lee DA, Peng G, Guo Z, Li Y, Kiniwa Y, Shevach EM, Wang RF (2004) Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. *Immunity* 20: 107
201. Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA (1996) Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. *J Exp Med* 184: 2207
202. Wang RF, Parkhurst MR, Kawakami Y, Robbins PF, Rosenberg SA (1996) Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. *J Exp Med* 183: 1131
203. Wang RF, Johnston SL, Southwood S, Sette A, Rosenberg SA (1998) Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33. *J Immunol* 160: 890
204. Wang RF, Johnston SL, Zeng G, Topalian SL, Schwartzentruber DJ, Rosenberg SA (1998) A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. *J Immunol* 161: 3598

205. Wang RF, Wang X, Atwood AC, Topalian SL, Rosenberg SA (1999) Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. *Science* 284: 1351
206. Wang RF, Wang X, Rosenberg SA (1999) Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells. *J Exp Med* 189: 1659
207. Weinschenk T, Gouttefangeas C, Schirle M, Obermayr F, Walter S, Schoor O, Kurek R, Loeser W, Bichler KH, Wernet D, Stevanovic S, Rammensee HG (2002) Integrated functional genomics approach for the design of patient-individual antitumor vaccines. *Cancer Res* 15: 5818
208. Wolfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Buschenfelde KH, Boon T (1994) Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. *Eur J Immunol* 24: 759
209. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer zum Buschenfelde KH, Beach D (1995) A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. *Science* 269: 1281
210. Worley BS, van den Broeke LT, Goletz TJ, Pendleton CD, Daschbach EM, Thomas EK, Marincola FM, Helman LJ, Berzofsky JA (2001) Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. *Cancer Res* 61: 6868
211. Yang D, Nakao M, Shichijo S, Sasatomi T, Takasu H, Matsumoto H, Mori K, Hayashi A, Yamana H, Shirouzu K, Itoh K (1999) Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. *Cancer Res* 59: 4056
212. Yasukawa M, Ohminami H, Kaneko S, Yakushijin Y, Nishimura Y, Inokuchi K, Miyakuni T, Nakao, S, Kishi K, Kubonishi I, Dan K, Fujita S (1998) CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner. *Blood* 92: 3355
213. Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant JP, Lemonnier FA, Leblond V, Langlade-Demoyen P (1998) Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. *J Clin Invest* 101: 2290

214. Yotnda P, Garcia F, Peuchmaur M, Grandchamp B, Duval M, Lemonnier F, Vilmer E, Langlade-Demoyen P (1998) Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. *J Clin Invest* 102: 455
215. Yun C, Senju S, Fujita H, Tsuji Y, Irie A, Matsushita S, Nishimura Y (1999) Augmentation of immune response by altered peptide ligands of the antigenic peptide in a human CD4+ T-cell clone reacting to TEL/AML1 fusion protein. *Tissue Antigens* 54: 153
216. Zarour HM, Kirkwood JM, Kierstead LS, Herr W, Brusic V, Slingluff CL Jr, Sidney J, Sette A, Storkus WJ (2000) Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. *Proc Natl Acad Sci USA* 97: 400
217. Zeng G, Touloukian CE, Wang X, Restifo NP, Rosenberg SA, Wang RF (2000) Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. *J Immunol* 165: 1153
218. Zhu B, Chen Z, Cheng X, Lin Z, Guo J, Jia Z, Zou L, Wang Z, Hu Y, Wang D, Wu Y (2003) Identification of HLA-A*0201-restricted cytotoxic T lymphocyte epitope from TRAG-3 antigen. *Clin Cancer Res* 9: 1850
219. Zorn E, Hercend T (1999) A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation. *Eur J Immunol* 29: 592
220. Zorn E, Hercend T (1999) A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion. *Eur J Immunol* 29: 602